Trial
NCT01832857
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Cornerstone Pharmaceuticals
Collaborators
—
Condition
Cancer
Intervention
CPI-613
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-29